4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025)

4D Molecular Therapeutics (FDMT) has 6 years of Capital Expenditures data on file, last reported at $4.3 million in Q4 2025.

• On a quarterly basis, Capital Expenditures rose 355.32% year-over-year to $4.3 million in Q4 2025; TTM through Mar 2026 was $4.8 million, a 48.85% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 30.14% from the prior year.
• Capital Expenditures for Q4 2025 stood at $4.3 million, up from -$91000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for FDMT reached as high as $6.4 million in Q1 2022 and fell as low as -$8.0 million in Q3 2022.
• Historically, Capital Expenditures has averaged $903400.0 across 5 years, with a median of $633500.0 in 2024.
• Across the five-year window, Capital Expenditures soared 4322.76% in 2022 and tumbled 351.82% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $5.1 million in 2021, then plunged by 108.63% to -$440000.0 in 2022, then tumbled by 351.82% to -$2.0 million in 2023, then jumped by 147.74% to $949000.0 in 2024, then surged by 355.32% to $4.3 million in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $4.3 million in Q4 2025, -$91000.0 in Q3 2025, and $557000.0 in Q2 2025.